Ripretinib
Last Updated: 06/30/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 168 publications
Quantification of buparlisib in human liver microsomes employing an ultra-fast, sensitive UPLC-MS/MS method: in vitro and in silico metabolic stability evaluation.
Journal: The Analyst
Published: January 27, 2026
Epidermal Growth Factor Receptor/KIT-Linked Proliferative Bias in Normal Breast Lobules from Matched Non-Hispanic Black and White Women Is Rapidly Reversible by Receptor Tyrosine Kinase Inhibition.
Journal: The American journal of pathology
Published: November 11, 2025
Gastrointestinal Stromal Tumors: Molecular Mechanisms of Drug Resistance and Advances in Therapeutic Strategies.
Journal: Journal of gastroenterology and hepatology
Published: October 19, 2025
Clinicopathologic and molecular spectrum of gastrointestinal stromal tumor (GIST) with NTRK fusion and marked response to larotrectinib in GIST with NTRK fusion: a case report.
Journal: Cellular oncology (Dordrecht, Netherlands)
Published: September 15, 2025
Correction: Gastrointestinal stromal tumors with the use of ripretinib and sunitinib: real-world adverse event analysis based on the FDA adverse event reporting system (FAERS).
Journal: Frontiers in pharmacology
Published: August 20, 2025
Ultra-Fast UPLC-MS/MS Method for the Ripretinib Quantification in the HLMs Matrix With Metabolic Stability Assessment: In-Silico Study for Toxic Alerts and the Metabolic Lability.
Journal: Archiv der Pharmazie
Published: August 11, 2025
Benign Keratoses With Inverted Follicular Keratosis-Like Features in a Patient Receiving Ripretinib: A Case Report.
Journal: Journal of cutaneous pathology
Published: August 09, 2025
Present management of gastrointestinal stromal tumors.
Journal: Klinicka onkologie : casopis Ceske a Slovenske onkologicke spolecnosti
Published: August 05, 2025
Last Updated: 06/30/2026